Chapter 34
Coronary Stent Technology
Neville Kukreja MA, MRCP,
Yoshinobu Onuma MD,
Patrick W. Serruys MD, PhD, FESC, FACC,
Neville Kukreja MA, MRCP
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorYoshinobu Onuma MD
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorPatrick W. Serruys MD, PhD, FESC, FACC
Professor of Medicine Head
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorNeville Kukreja MA, MRCP,
Yoshinobu Onuma MD,
Patrick W. Serruys MD, PhD, FESC, FACC,
Neville Kukreja MA, MRCP
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorYoshinobu Onuma MD
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorPatrick W. Serruys MD, PhD, FESC, FACC
Professor of Medicine Head
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Search for more papers by this authorBook Editor(s):Jürgen Haase MD, PhD, FESC, FACC,
Hans-Joachim Schäfers MD, PhD,
Horst Sievert MD, FESC, FACC,
Ron Waksman MD, FACC,
Jürgen Haase MD, PhD, FESC, FACC
Professor of Medicine Consultant Cardiologist
Kardiocentrum Frankfurt, Klinik Rotes Kreuz, Frankfurt/Main, Germany
Search for more papers by this authorHans-Joachim Schäfers MD, PhD
Professor of Surgery Chair
Department of Thoracic and Cardiovascular Surgery, University Hospital Saarland, Homburg/Saar, Germany
Search for more papers by this authorHorst Sievert MD, FESC, FACC
Professor of Medicine Head
Department of Cardiology, CardioVascular Center Frankfurt, Frankfurt, Germany
Search for more papers by this authorRon Waksman MD, FACC
Professor of Medicine Associate Director Director
Division of Cardiology, Washington, DC, USA
Experimental Cardiology, Washington Hospital Center, Washington, DC, USA
Search for more papers by this authorFirst published: 10 May 2010
Summary
This chapter contains sections titled:
-
Introduction
-
Plain old balloon angioplasty and the arrival of coronary stents
-
Developments in bare metal stent technology
-
First generation drug-eluting stents
-
Safety concerns and scope for improvement
-
Second-generation drug-eluting stents
-
New permanent metallic platforms
-
Novel stent coatings
-
New drugs and combinations
-
Fully biodegradable platforms
-
When should drug-eluting stents be used?
-
The future
-
Conclusion
-
Note
-
References
References
- Praz L, Cook S, & Meier B (2008) Percutaneous coronary interventions in Europe in 2005. EuroIntervention 3: 442–446.
- Morice MC, Serruys PW, Sousa JE, et al. (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773–1780.
- McFadden EP, Stabile E, Regar E, et al. (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of anti-platelet therapy. Lancet 364: 1519–1521.
- Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, & Serruys PW (2005) Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45: 2088–2092.
- Iakovou I, Schmidt T, Bonizzoni E, et al. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126–2130.
- Daemen J, Wenaweser P, Tsuchida K, et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxeleluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369: 667–678.
- Grüntzig A (1978) Transluminal dilatation of coronary-artery stenosis. Lancet 1: 263.
- Grüntzig A, Senning A, & Siegenthaler W (1979) Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 301: 61–68.
- Sigwart U, Puel J, Mirkovitch V, Joffre F, & Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316: 701–706.
- Serruys PW, de Jaegere P, Kiemeneij F, et al. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331: 489–495.
- Fischman DL, Leon MB, Baim DS, et al. (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331: 496–501.
- Serruys PW, Strauss BH, Beatt KJ, et al. (1991) Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 324: 13–17.
- Schomig A, Neumann F-J, Kastrati A, et al. (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334: 1084–1089.
- Colombo A, Hall P, Nakamura S, et al. (1995) Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91: 1676–1688.
- Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH, & Investigators ftC (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102: 624–629.
- Rajagopal V & Rockson SG (2003) Coronary restenosis: a review of mechanisms and management. Am J Med 115: 547–553.
- Flueckiger F, Sternthal H, Klein GE, Aschauer M, Szolar D, & Kleinhappl G (1994) Strength, elasticity, and plasticity of expandable metal stents: in vitro studies with three types of stress. J Vasc Interv Radiol 5: 745–750.
- Lossef SV, Lutz RJ, Mundorf J, & Barth KH (1994) Comparison of mechanical deformation properties of metallic stents with use of stress-strain analysis. J Vasc Interv Radiol 5: 341–349.
- Okabe T, Asakura Y, Ishikawa S, Asakura K, Mitamura H, & Ogawa S (1999) Evaluation of scaffolding effects of five different types of stents by intravascular ultrasound analysis. Am J Cardiol 84: 981–986.
- Carrozza JP, Jr., Hosley SE, Md DJC, & Baim DS (1999) In vivo assessment of stent expansion and recoil in normal porcine coronary arteries: differential outcome by stent design. Circulation 100: 756–760.
- Palmaz JC, et al. (1985) Expandable intraluminal graft: a preliminary study. Work in progress. Radiology 156: 73–77.
- Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, & Reuter S (1987) Balloon-expandable intracoronary stents in the adult dog. Circulation 76: 450–457.
- Schatz RA, Baim DS, Leon M, et al. (1991) Clinical experience with the palmaz-schatz coronary stent: initial results of a multicenter study. Circulation 83: 148–161.
- Kastrati A, Mehilli J, Dirschinger J, et al. (2001) Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation 103: 2816–2821.
- Pache Ju, Kastrati A, Mehilli J, et al. (2003) Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial. J Am Coll Cardiol 41: 1283–1288.
- Kereiakes DJ, Cox DA, Hermiller JB, et al. (2003) Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 92: 463–466.
- Sketch JMH, Ball M, Rutherford B, Popma JJ, Russell C, & Kereiakes DJ (2005) Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol 95: 8–12.
- Wong SC, Kent KM, Mintz GS, et al. (1995) Percutaneous transcatheter repair of a coronary aneurysm using a composite autologous cephalic vein-coated Palmaz-Schatz biliary stent. Am J Cardiol 76: 990–991.
- Stefanadis C & Toutouzas P (1995) Percutaneous implantation of autologous vein graft stent for treatment of coronary artery disease. Lancet 345: 1509.
- Gercken U, Lansky AJ, Buellesfeld L, et al. (2002) Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results. Catheter Cardiovasc Interv 56: 353–360.
- Schächinger V, Hamm CW, Munzel T, et al. (2003) A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 42: 1360–1369.
- Stankovic G, Colombo A, Presbitero P, et al. (2003) Randomized evaluation of polyte trafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of Polytetrafluoroethylene Covered stent in Saphenous Vein Grafts (RECOVERS) Trial. Circulation 108: 37–42.
- Papafaklis M, Sianos G, Cost B, et al. (2006) Clinical and angio-graphic follow-up after overlapping implantation of polytetrafluoroethylene covered stents with drug eluting stents. EuroIntervention 2: 218–223.
- Laarman GJ, Kiemeneij F, Mueller R, et al. (2005) Feasibility, safety, and preliminary efficacy of a novel ePTFE-covered self-expanding stent in saphenous vein graft lesions: the Symbiot II trial. Catheter Cardiovasc Interv 64: 361–368.
- Turco MA, Buchbinder M, Popma JJ, et al. (2006) Pivotal, randomized US study of the Symbiot covered stent system in patients with saphenous vein graft disease: eight-month angio-graphic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 68: 379–388.
- Serruys PW, van Hout B, Bonnier H, et al. (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352(9129): 673–681.
- Kastrati A, Schomig A, Dirschinger J, et al. (2000) Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 101: 2478–2483.
- vom Dahl J, Haager PK, Grube E, et al. (2002) Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. Am J Cardiol 89: 801–805.
- Unverdorben M, Sippel B, Degenhardt R, et al. (2003) Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome. Am Heart J 145: E17.
- Haase J, Storger H, Hofmann M, Schwarz CE, Reinemer H, & Schwarz F (2003) Comparison of stainless steel stents coated with turbostratic carbon and uncoated stents for percutaneous coronary interventions. J Invasive Cardiol 15: 562–565.
- Windecker S, Simon R, Lins M, et al. (2005) Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX Trial. Circulation 111: 2617–2622.
-
Giraud-Sauveur Y (2007) TITAN 2 bio-active stent (BAS) with titanium-NO. EuroIntervention 3: 526–528.
10.4244/EIJV3I4A92 Google Scholar
- Moses JW, Leon MB, Popma JJ, et al. (2003) Sirolimus-eluting stents versus stand ard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315–1323.
- Stone GW, Ellis SG, Cox DA, et al. (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350: 221–231.
- Stone GW, Ellis SG, Cannon L, et al. (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294: 1215–1223.
- Serruys PW, Ong ATL, Morice M-C, et al. (2005) Arterial Revascularisation Therapies Study Part II–Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 1: 147–156.
- Ong AT, Serruys PW, Aoki J, et al. (2005) The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45: 1135–1141.
- Daemen J, Ong AT, Stefanini GG, et al. (2006) Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98: 895–901.
- Daemen J & Serruys PW (2007) Drug-eluting stent update (2007): Part I: a survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 116: 316–328.
- Finn AV, Nakazawa G, Joner M, et al. (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500–1510.
- Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715–2729.
- Burke SE, Lubbers NL, Chen YW, et al. (1999) Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 33: 829–835.
- Gallo R, Padurean A, Jayaraman T, et al. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 2164–2170.
- Marx SO & Marks AR (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104: 852–855.
- Sousa JE, Costa MA, Abizaid A, et al. (2001) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103: 192–195.
- Rensing BJ, Vos J, Smits PC, et al. (2001) Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 22: 2125–2130.
- Schofer J, Schluter M, Gershlick AH, et al. (2003) Sirolimuseluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362(9390): 1093–1099.
- Schampaert E, Cohen EA, Schluter M, et al. (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43: 1110–1115.
- Lemos PA, Hoye A, Goedhart D, et al. (2004) Clinical, angio-graphic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Study. Circulation 109: 1366–1370.
- Urban P, Gershlick AH, Guagliumi G, et al. (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-cypher registry. Circulation 113: 1434–1441.
- Kastrati A, Mehilli J, Pache J, et al. (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 1030–1039.
- Spaulding C, Daemen J, Boersma E, Cutlip DE, & Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 989–997.
- Steffel J, Latini RA, Akhmedov A, et al. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112: 2002–2011.
- Imanishi T, Kobayashi K, Kuki S, Takahashi C, & Akasaka T (2006) Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 189: 288–296.
- Muldowney JA, 3rd, Stringham JR, Levy SE, et al. (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27: 400–406.
- Togni M, Windecker S, Cocchia R, et al. (2005) Sirolimuseluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46: 231–236.
- Hofma SH, van der Giessen WJ, van Dalen BM, et al. (2006) Indication of long-term endothelial dysfunction after sirolimuseluting stent implantation. Eur Heart J 27: 166–170.
- Obata JE, Kitta Y, Takano H, et al. (2007) Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 50: 1305–1309.
- Fuke S, Maekawa K, Kawamoto K, et al. (2007) Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 71: 220–225.
- Stone GW, Ellis SG, Cox DA, et al. (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS Stent: the TAXUS-IV Trial. Circulation 109: 1942–1947.
- Ong ATL, Serruys PW, Aoki J, et al. (2005) The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45: 1135–1141.
- Grube E, Dawkins KD, Guagliumi G, et al. (2007) TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 28: 2578–2582.
- Daemen J, Tsuchida K, Stefanini GG, et al. (2006) Two-year clinical follow-up of the unrestricted use of the paclitaxeleluting stent compared to the sirolimus-eluting stent as part of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) Registry. EuroIntervention 2: 330–337.
- Daemen J, Spaulding C, Jacob S, Boersma E, Varenne O, & Serruys P (2007) A pooled safety analysis of data comparing paclitaxel-eluting stents with bare-metal stents. EuroIntervention 3: 392–399.
- Colombo A, Drzewiecki J, Banning A, et al. (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108: 788–794.
- Stahli BE, Camici GG, Steffel J, et al. (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99: 149–155.
- Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D'Agostino R, & Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020–1029.
- Finn AV, Joner M, Nakazawa G, et al. (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelializa tion. Circulation 115: 2435–2441.
- Lagerqvist B, James SK, Stenestrand U, et al. (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356: 1009–1019.
- de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. (2008) Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio Espanol sobre Trombosis de stents Farma coactivos). J Am Coll Cardiol 51: 986–990.
- Kuchulakanti PK, Chu WW, Torguson R, et al. (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108–1113.
- Park D-W, Park S-W, Park K-H, et al. (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98: 352–356.
- Okabe T, Mintz GS, Buch AN, et al. (2007) Intravascular ultra-sound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 100: 615–620.
- Win HK, Caldera AE, Maresh K, et al. (2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297: 2001–2009.
- Farb A, Burke AP, Kolodgie FD, & Virmani R (2003) Pathological mechanisms of fatal late cor onary stent thrombosis in humans. Circulation 108: 1701–1706.
- Joner M, Finn AV, Farb A, et al. (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48: 193–202.
- Awata M, Kotani J-i, Uematsu M, et al. (2007) Serial angioscopic evidence of incomplete neointimal coverage after sirolimuseluting stent implantation: comparison with bare-metal stents. Circulation 116: 910–916.
- Kotani J-i, Awata M, Nanto S, et al. (2006) Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47: 2108–2111.
- van der Giessen WJ, Lincoff AM, Schwartz RS, et al. (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94: 1690–1697.
- Virmani R, Guagliumi G, Farb A, et al. (2004) Localized hyper-sensitivity and late coronary thrombosis secondary to a sirolimuseluting stent: should we be cautious? Circulation 109: 701–705.
- Nebeker JR, Virmani R, Bennett CL, et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47: 175–181.
- Stettler C, Wandel S, Allemann S, et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591): 937–948.
- Williams DO, Abbott JD, Kip KE, for the DI (2006) Outcomes of 6906 patients under going percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 114: 2154–2162.
- Jensen LO, Maeng M, Kaltoft A, et al. (2007) Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50: 463–470.
- Tu JV, Bowen J, Chiu M, et al. (2007) Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357: 1393–1402.
- Marzocchi A, Saia F, Piovaccari G, et al. (2007) Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (registro angioplastiche dell'emilia romagna) multicenter registry. Circulation 115: 3181–3188.
- Abbott JD, Voss MR, Nakamura M, et al. (2007) Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the national heart, lung, and blood institute dynamic registry. J Am Coll Cardiol 50: 2029–2036.
- Serruys PW & Daemen J (2007) The SCAAR registry or the Swedish yo-yo. EuroIntervention 3: 297–300.
- Beohar N, Davidson CJ, Kip KE, et al. (2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297: 1992–2000.
- Spaulding C, Henry P, Teiger E, et al. (2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355: 1093–1104.
- Laarman GJ, Suttorp MJ, Dirksen MT, et al. (2006) Paclitaxeleluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355: 1105–1113.
- Marroquin OC, Selzer F, Mulukutla SR, et al. (2008) A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358: 342–352.
- Roy P, Buch AN, Javaid A, et al. (2008) Impact of “off-label” utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. The Am J Cardiol 101(3): pp. 293–299.
- Meredith IT, Ormiston JA, Whitbourn R, et al. (2005) First-inhuman study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 1: 157–164.
- Meredith IT, Ormiston J, Whitbourn R, et al. (2007) Four-year clinical follow-up after implantation of the endeavor zotarolimuseluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol. Integrating Safety into the Practice of Drug-Eluting Stent Deployment 100(8 Suppl. 2, ): S56–S61.
- Fajadet J, Wijns W, Laarman G-J, et al. (2006) Randomized, double-blind, multicenter study of the endeavor zotarolimuseluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114: 798–806.
- Kandzari DE, Leon MB, Popma JJ, et al. (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48: 2440–2447.
- Schuler W, Sedrani R, Cottens S, et al. (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64: 36–42.
- Serruys PW, Ong ATL, Piek JJ, et al. (2005) A randomized comparison of a durable polymer Everolimus-eluting stent with bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1: 58–65.
- Tsuchida K, Piek JJ, Neumann F, et al. (2005) One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 1: 266–272.
- Beijk MA, Neumann F, Wiemer M, et al. (2007) Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (the SPIRIT FIRST Trial). EuroIntervention 3: 206–212.
- Serruys PW, Ruygrok P, Neuzner J, et al. (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Euro-Intervention 2: 286–294.
- Aoki J, Ong ATL, Abizaid A, et al. (2005) One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer–insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroIntervention 1: 165–172.
- Serruys PW, Sianos G, Abizaid A, et al. (2005) The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46: 253–260.
- Dawkins K, Verheye S, Schühlen H, et al. (2007) The European Cobalt Stent with Antiproliferative for Restenosis Trial (Euro-STAR): 12 month results. EuroIntervention 3: 82–88.
- Abizaid AC, De Ribamar Costa J, Whitbourn RJ, & Chang JC (2007) The CardioMind coronary stent delivery system: stent delivery on a.014” guidewire platform. EuroIntervention 3: 154–157.
- Evans LW, Doran P, & Marco P (2007) XTENT® Custom NX™ drug eluting stent systems. EuroIntervention 3: 158–161.
- Ormiston JA, Webster MWI, Jack SE, et al. (2006) Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies. Catheter Cardiovasc Interv 67: 49–55.
- Lefevre T, Ormiston J, Guagliumi G, et al. (2005) The FRONTIER stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurca tion coronary artery lesions. J Am Coll Cardiol 46: 592–598.
- Duchamp J & Boeke-Purkis K (2007) Abbott Vascular's everolimus eluting side branch access stent. EuroIntervention 2: 509–511.
- Verheye S & Trauthen B (2007) AXXESS™ Biolimus A9® eluting bifurcation stent system. EuroIntervention 2: 506–508.
- Grube E, Buellesfeld L, Neumann FJ, et al. (2007) Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 99: 1691–1697.
- Miyazawa A, Ako J, Hassan A, et al. (2007) Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial. Catheter Cardiovasc Interv 70: 952–957.
- Kaplan A, Ramcharitar S, Louvard Y, et al. (2007) Tryton I, First-In-Man (FIM) study: acute and 30 day outcomes: preliminary report. EuroIntervention 3: 54–9.
- Onuma Y, Müller R, Ramcharitar S, et al. (2008) Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroIntervention 3: 546–552.
- Laborde J-C, Borenstein N, Behr L, & Ramcharitar S (2007) Stentys coronary bifurcation stent. EuroIntervention 3: 162–165.
- Ormiston J, Webster M, El-Jack S, McNab D, & Plaumann SS (2007) The AST petal dedicated bifurcation stent: first-in-human experience. Catheter Cardiovasc Interv 70: 335–340.
- Ge J, Qian J, Wang X, et al. (2007) Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv 69: 198–202.
- Lee CH, Lim J, Low A, et al. (2007) Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). J Invasive Cardiol 19: 182–185.
- Vranckx P, Serruys PW, Gambhir S, et al. (2006) Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2: 310–317.
- Grube E, Sonoda S, Ikeno F, et al. (2004) Six- and twelve-month results from first human experience using everolimuseluting stents with bioabsorbable polymer. Circulation 109: 2168–2171.
- Costa RA, Lansky AJ, Mintz GS, et al. (2005) Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 95: 113–116.
- Tsuchiya Y, Lansky AJ, Costa RA, et al. (2006) Effect of everolimuseluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 98: 464–469.
- Meredith I, Worthley S, Whitbourn R, et al. (2007) The next-generation Endeavor™ Resolute™ stent: 4-month clinical and angiographic results from the Resolute™ first-in-man trial. EuroIntervention 3: pp. 50–53.
- Wessely R, Hausleiter J, Michaelis C, et al. (2005) Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25: 748–753.
- Mehilli J, Kastrati A, Wessely R, et al. (2006) Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113: 273–279.
- Rajtar A, Kaluza G, Yang Q, et al. (2006) Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2: 113–115.
- Kollum M, Farb A, Schreiber R, et al. (2005) Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of rest-enosis. Catheter Cardiovasc Interv 64: 85–90.
- Grube E, Hauptmann K-E, Buellesfeld L, Lim V, & Abizaid A (2005) Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 1: 53–57.
- Costa RA, Lansky AJ, Abizaid A, et al. (2006) Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. The Am J Cardiol 98: 443–446.
- Chevalier B, Serruys PW, Silber S, et al. (2007) Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2: 426–434.
- Matter CM, Rozenberg I, Jaschko A, et al. (2006) Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48: 286–292.
- Mohacsi PJ, Tuller D, Hulliger B, & Wijngaard PL (1997) Different inhibitory effects of immuno suppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transpl 16: 484–492.
- Morice M-C, Bestehorn H-P, Carrie D, et al. (2006) Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbo stents. The randomized JUPITER II trial. EuroIntervention 2: 45–52.
- Tanimoto S, van der Giessen W, van Beusekom H, et al. (2007) MAHOROBA™: Kaneka's tacrolimus eluting coronary stent. EuroIntervention 3: 149–153.
- Aoki J, Serruys PW, van Beusekom H, et al. (2005) Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45: 1574–1579.
- Duckers HJ, Silber S, Winter RD, et al. (2007) Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 3: 67–75.
- Duckers HJ, Soullié T, Heijer PD, et al. (2007) Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention 3: 350–358.
- Co M, Tay E, Lee CH, et al. (2008) Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J 155: 128–132.
- Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Vermani R, & Kipshidze N (2006) First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 47: 7–10.
-
Stefanadis C, Toutouzas K, Tsiamis E, Vavuranakis M, Stefanadi E, & Kipshidze N (2007) First-in-man study with bevacizumabeluting stent: a new approach for the inhibition of atheromatic plaque neovascularisation. EuroIntervention 3: 460–464.
10.4244/EIJV3I4A82 Google Scholar
- Tamai H, Igaki K, Kyo E, et al. (2000) Initial and 6-month results of biodegra dable poly-l-lactic acid coronary stents in humans. Circulation 102: 399–404.
- Ormiston JA, Webster MW, & Armstrong G (2007) First-inhuman implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 69: 128–31.
- Ormiston JA, Serruys PW, Regar E, et al. (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371: 899–907.
- Tanimoto S, Serruys PW, Thuesen L, et al. (2007) Comparison of in vivo acute stent recoil between the bioabsorbable everolimuseluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 70: 515–523.
- Kukreja N, Otsuka M, van Mieghem C, Ligthart J, Sianos G, & Serruys P (2006) Biodegradable drug eluting stents: invasive and non-invasive imaging. EuroIntervention 2: 403.
- Erbel R, Di Mario C, Bartunek J, et al. (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369: 1869–1875.
- Eggebrecht H, Rodermann J, Hunold P, et al. (2005) Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 112: e303–304.
- Bose D, Eggebrecht H, & Erbel R (2006) Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. Heart 92: 892.
- National Institute for Health and Clinical Excellence (2008) Final appraisal determination: drug-eluting stents for the treatment of coronary artery disease. Available at: http://www.nice. org.uk/nicemedia/pdf/TA152Guidance.pdf
- Cohen DJ, Bakhai A, Shi C, et al. (2004) Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation 110: 508–514.
- Bakhai A, Stone GW, Mahoney E, et al. (2006) Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revas cularization: results from the TAXUS-IV Trial. J Am Coll Cardiol 48: 253–261.
- Ong AT, Daemen J, van Hout BA, et al. (2006) Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH registry. Eur Heart J 27: 2996–3003.
- Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. (2007) Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 370(9598): 1552–1559.
- van Beusekom HM, Saia F, Zindler JD, et al. (2007) Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 28: 974–979.
